• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 12, 2023 at 11:02: AM
via Madrigal Pharmaceuticals’ CEO Paul Friedman, M.D., is stepping aside so Sanofi’s Bill Sibold can take the reins ahead of a possible FDA greenlight for what would be the first treatment approved for nonalcoholic steatohepatitis (NASH).

article source
 

<



Similar threads

cafead
Madrigal&#039;s Rezdiffra off to strong start, but &#039;bumpiness&#039; is coming: analyst
Replies
0
Views
27
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Viking&#039;s MASH drug scored where Madrigal&#039;s didn&#039;t, but shares fall on lack of direction
Replies
1
Views
108
Pharma/Biotech Companies - In the News
anonymous
cafead
Here&#039;s Why Madrigal Pharmaceuticals Fell 39.4% in November
Replies
0
Views
221
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra...
Replies
0
Views
58
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
Replies
0
Views
196
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote